Detalles de la búsqueda
1.
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Lancet
; 401(10392): 1929-1940, 2023 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37156252
2.
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Diabetes Obes Metab
; 22(4): 658-668, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858673
3.
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Lancet Diabetes Endocrinol
; 11(6): 414-425, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148899
4.
DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
J Diabetes
; 14(6): 401-413, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762390
5.
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
Diabetes Care
; 44(7): 1595-1603, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33875484
Resultados
1 -
5
de 5
1
Próxima >
>>